Yazarlar : Kasamon YL, Jacene HA, Gocke CD et al

Yayın : Blood

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22343727

Konu : Lenfoma

Literatür İçeriği :  

Abstract

In classical Hodgkin lymphoma (cHL), circulating clonotypic malignant cells express CD20, potentially explaining the observed activity of rituximab. This multicenter phase II study investigated the combination of rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated cHL. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20(+) Hodgkin and Reed-Sternberg cells. Rituximab-ABVD was generally well-tolerated. Delivered relative dose intensity was 94% for AVD and 79% for bleomycin. After 6 cycles, 81% were in complete remission. Only 8% received radiation therapy. The actuarial 3-year event-free and overall survivals were 83% and 98%. Epstein-Barr virus (EBV) copy number in plasma fell dramatically during cycle 1 in patients with EBV(+) tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < 0.05). Rituximab-ABVD and clonotypic B cells warrant additional study in cHL. The trial was registered at www.clinicaltrials.gov, NCT00369681.

Literatür Arşivi